Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2026-06-05 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a regulatory ‘Next Day Disclosure Return’ (Form FF305) filed on the HKEx, detailing changes in issued shares and treasury shares including a specific share repurchase. It is not an Annual Report or 10-K, nor an earnings release or management commentary; instead it clearly reports the company’s own share transactions (buyback/treasury sales). Under FinancialReports definitions, this falls under Transaction in Own Shares (POS).
2026-06-05 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR AND MANAGEMENT
Director's Dealing Classification · 92% confidence The document is a voluntary announcement disclosing insider transactions: the executive Director (Dr. Xu) and certain members of management purchased shares on the open market, increasing their holdings. This falls squarely under Director’s Dealing, which reports personal share transactions by company directors and executives.
2026-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Share Issue/Capital Change Classification · 75% confidence The document is a mandated monthly return to the Hong Kong Stock Exchange (Form FF301) detailing movements in authorised/issued share capital, share option exercises, treasury shares, public float confirmation, and related confirmations under the Listing Rules. It is not an earnings report, management change, or a simple publication announcement but a detailed disclosure of share issuance and capital changes during the reporting month. This fits the definition of a Share Issue/Capital Change announcement (Code: SHA).
2026-06-04 English
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 79% confidence The document is a voluntary corporate announcement by Alphamab Oncology about clinical research updates and ASCO presentation details. It does not contain financial results, management changes, proxy materials, or formal report attachments. It is a general regulatory announcement/fallback category for miscellaneous company disclosures under Hong Kong Listing Rules. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-06-02 English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement on the Stock Exchange of Hong Kong about clinical trial results for Anbenitamab. It contains no financial statements, earnings data, management changes, or share transactions – it is simply an operational update. It is not an investor presentation, earnings release, or any other specific filing type. Therefore it falls into the general “Regulatory Filings” category for miscellaneous announcements (RNS).
2026-06-01 English
INSIDE INFORMATION ANNOUNCEMENT - ANBENITAMAB INJECTION OBTAINED MARKETING APPROVAL FROM THE NMPA
Regulatory Filings Classification · 90% confidence The document is an “Inside Information Announcement” made under the Hong Kong Listing Rules (Rule 13.09(2)(a) and Part XIVA of the Securities and Futures Ordinance). It contains regulatory boilerplate (HKEX disclaimer), discloses material corporate information (marketing approval from the NMPA) but does not include financial results, management discussion, or any vote results. It is not a full report (Annual, Interim, ESG, etc.) nor a proxy or meeting material. Therefore it should be classified as a general regulatory announcement (Regulatory Filings).
2026-05-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.